Respiratorius is a company that develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and severe asthma. It develops drugs supporting the effects of the treatment of diffuse large B-cell lymphoma. In addition, the company offers compound series with a bronchodilating effect on human lung tissue. Respiratorius’s project portfolio also contains a substance developed for use in PET (positron emission tomography) imaging, aimed at facilitating the diagnosis of certain cardiovascular diseases.